01 / Fit
Who typically evaluates an international sourcing pathway?
Search demand in this market comes from several groups with different responsibilities. Self-funded employers and health plans are usually evaluating claims exposure, plan design, member communication, and stop-loss implications. Brokers, TPAs, and benefits consultants need a repeatable diligence framework they can explain to clients. Pharmacies and sourcing teams focus more closely on product identity, licensed counterparties, package details, documentation, and handling requirements.
A useful first review starts with a specific product, strength, dosage form, package, destination, and intended use. Broad promises such as “all drugs are available” or “every shipment is legal” are not credible because FDA requirements, product approval status, controlled-substance rules, state requirements, pharmacy rules, and the intended transaction can change the analysis.
02 / Evaluation
The six controls a buyer should examine
| Control | Evidence to request | Why it matters |
|---|---|---|
| Product identity | Brand, active ingredient, strength, dosage form, pack size, manufacturer, and market authorization | Look-alike names and non-equivalent packages can invalidate a price comparison. |
| Counterparty status | Pharmacy or distributor license, national-register entry, and applicable authorization | A logo or certificate image alone is not enough; it should resolve to an authoritative register. |
| Price basis | Dated source, currency, package quantity, exclusions, and U.S. benchmark type | Cash price, WAC, net plan cost, and patient out-of-pocket cost are different measures. |
| Regulatory route | Product-specific legal and admissibility review | FDA states that imported prescription drugs must satisfy applicable U.S. requirements; personal-import discretion is narrow and case-specific. |
| Handling | Storage label, qualified packaging, lane plan, tracking, and excursion procedure | Temperature-sensitive products require more than expedited delivery. |
| Accountability | Named contacts, written scope, corrections process, privacy terms, and escalation route | The buyer needs to know who owns each handoff and what happens when conditions change. |
03 / Process
A responsible sourcing review is a sequence, not a shortcut
- Define the request.Record the exact medication, strength, dosage form, package quantity, destination, timing, and organization type.
- Verify the reference.Match the EU-listed product to the intended U.S. comparison and identify material packaging or labeling differences.
- Check licensed counterparties.Confirm the dispensing or distribution authorization using the relevant national or EU register.
- Review price and handling.Normalize quantities and currencies, then determine whether storage, cold chain, or controlled handling changes feasibility.
- Assess the route.Obtain appropriate regulatory, pharmacy, clinical, and logistics review before relying on any proposed pathway.
- Document the decision.Keep the source dates, assumptions, exclusions, and responsible parties attached to the case.
04 / Procurement
Questions to ask a prospective sourcing partner
- Are you a pharmacy, distributor, broker, consultant, or technology platform?
- Which entity would dispense or distribute the product, and where can its authorization be verified?
- Is the displayed price a live quote, a dated reference, or a broad benchmark?
- How are package quantity, dosage form, currency, fees, and shipping normalized?
- Who evaluates FDA admissibility and state-level requirements for this exact case?
- How are temperature requirements verified, monitored, and escalated after an excursion?
- What patient or prescription data is collected, by whom, and under which privacy terms?
- What happens if the product, route, price, or availability changes after the initial review?
05 / Scope
Where US Med Access fits
US Med Access publishes dated product and package references, organizes EU-versus-U.S. price context, and supports case-specific introductions and research. It is not a pharmacy, manufacturer, compounder, wholesaler, or direct seller. That distinction is intentional: a useful sourcing decision should separate reference research from dispensing, distribution, clinical judgment, and regulatory approval.
Organizations can begin with the medication catalog, review the pricing methodology, and submit a package-level request when they are ready to evaluate a specific case.
Frequently asked questions
Clear answers for the next decision.
01Is international prescription sourcing automatically legal in the United States?
No. The route, product, intended recipient, approval status, transaction, and applicable federal and state requirements must be reviewed. A sourcing reference is not legal authorization or a guarantee of admissibility.
02Is an international sourcing service the same as an online pharmacy?
Not necessarily. A consultant, broker, benefit program, distributor, and licensed dispensing pharmacy have different roles. Buyers should identify the exact entity responsible for each step.
03Can a health plan compare international prices with PBM claims?
Yes, as an initial opportunity analysis, but the comparison must normalize product, package, quantity, currency, rebates, fees, and benefit design. A broad list price should not be treated as the final plan cost.
04What should a buyer verify first?
Start with the exact product and package, then verify the counterparty authorization, price basis, intended route, and handling requirements before relying on savings estimates.
Primary and authoritative sources
Sources used for this guide
- FDA: Human Drug Imports
- FDA: Importing Prescription Drugs
- European Commission: Falsified Medicines
- HHS ASPE: U.S. and International Drug Price Comparisons
This page is general information, not medical or legal advice. Requirements and source pages can change; verify the current rule for the specific product and route.